Pharmacological treatment of obesity offers new opportunities for long-term weight reduction, especially when previous methods have not brought results. Find out which obesity medications are available in Poland, how they work, who can benefit from them, and whether they are safe and effective in light of the latest studies.
Learn which medications for obesity are available, how they work, for whom they are intended, and whether they are safe and effective. The latest research and expert advice.
Table of Contents
- Pharmacological Treatment of Obesity – Who Is It For?
- How Do Obesity Medications Work? Mechanisms and Types
- The Most Popular Obesity Medications Available in Poland
- Effectiveness of Pharmacological Treatment of Obesity
- Obesity Medications and Heart Safety
- Obesity Medications as Support for a Healthy Lifestyle
Pharmacological Treatment of Obesity – Who Is It For?
Pharmacological treatment of obesity is not intended for every person with excess weight, and it certainly should not be treated as an “easier way” instead of lifestyle changes. According to current guidelines from the Polish Diabetes Association, the European Association for the Study of Obesity (EASO), or the American Endocrine Society, obesity medications are primarily considered for adults with a BMI ≥30 kg/m², or with a BMI ≥27 kg/m² if obesity-related comorbidities are present, such as type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, non-alcoholic fatty liver disease (NAFLD), polycystic ovary syndrome (PCOS), osteoarthritis, or cardiovascular diseases. In practical terms, this means that a person with moderate overweight but high cardiovascular risk or existing chronic disease may qualify for pharmacological treatment sooner than someone with a similar BMI but no complications. Another important criterion is the ineffectiveness of previous, properly conducted weight loss attempts based on diet, physical activity, and behavioral changes—typically, a doctor expects the patient to have followed non-pharmacological recommendations for at least 3–6 months, yet failed to lose approximately 5% of their initial weight.
Therefore, obesity medications target individuals whose weight problem is chronic, long-standing, well-documented, and genuinely threatening health or already causing metabolic complications. Another group for whom pharmacotherapy may be indicated are patients preparing for bariatric surgery—here, the physician may recommend medications for initial weight reduction, better glucose control, and blood pressure, thereby reducing perioperative risks. In some cases, pharmacotherapy is also used after bariatric surgery if, after a few years, weight gain recurs or it is difficult to maintain results—however, this is always a highly individualized decision made in collaboration with the bariatric team. It is also important not to overlook patients whose excess weight significantly reduces their quality of life: hinders daily mobility, impairs job performance, physical activity, or affects mental health, intensifying symptoms of depression and anxiety. In such cases, the doctor may consider that pharmacotherapy will support lifestyle change rather than substitute it, after a thorough health assessment and review of previous treatments.
Pharmacological treatment of obesity is generally not suitable for individuals with mild overweight and no complications, those seeking a “quick fix” for an upcoming event or trip, or patients unwilling to commit to dietary and activity changes—since in these cases, the potential risks and costs outweigh the expected benefits.
There are also numerous contraindications and limitations narrowing the population eligible for obesity medications—depending both on the specific active substance and the patient’s general health. For example, certain incretin drugs (GLP-1 and GIP/GLP‑1 agonists) are currently not recommended for those with a history of medullary thyroid cancer, MEN 2 syndromes, or some patients with severe gastrointestinal disease; other medications should not be used in certain heart conditions, psychiatric disorders, or severe kidney and liver failure. Obesity medications are generally contraindicated during pregnancy and breastfeeding; women of childbearing age must use effective contraception and plan medication discontinuation well ahead of conception. Therefore, self-medication for weight loss should never be undertaken—proper therapy requires a thorough medical history, laboratory tests (including liver and kidney function, lipid profile, glucose and HbA1c), blood pressure measurement, and analysis of current medications for interactions. A crucial, often-overlooked criterion is the patient’s readiness for long-term therapy: obesity is a chronic condition, and most available medications are intended for long-term use, often months or years. Patients must be aware that discontinuation usually leads to partial weight regain, and sustaining results requires permanent changes in eating and activity habits. Financial and access issues are also relevant—not all preparations are reimbursed, and the monthly cost of modern incretin medications remains high, so clinical recommendations often clash with patients’ real world possibilities.
Thus, qualifying for pharmacological obesity treatment is always an individualized process: the physician combines formal BMI and comorbidity criteria with assessment of cardiovascular risk, mental health, previous weight loss methods, willingness to cooperate, and therapeutic expectations. Well-conducted qualification steers medications towards those who will benefit most in terms of health and are able to participate safely and consistently in the long-term treatment process for this chronic disease.
How Do Obesity Medications Work? Mechanisms and Types
The medications used in obesity treatment differ in their mechanisms of action, but their common goal is to support long-term weight reduction by influencing the body’s energy balance – by lowering caloric intake, reducing absorption, or changing how the body processes energy. Simply put, they can be divided into several main groups: drugs affecting appetite and satiety centers in the brain, preparations reducing fat absorption in the digestive tract, medications modulating glucose-insulin metabolism, and older, sympathomimetic drugs suppressing appetite by stimulating the nervous system.
Modern pharmacotherapy of obesity is increasingly based on the complex understanding of appetite and metabolism regulation – with key roles for gut hormones such as GLP-1, GIP, leptin, and ghrelin, as well as neurotransmitters in the central nervous system (e.g., serotonin, dopamine, noradrenaline). The most talked-about drugs in recent years are incretin medications, i.e., GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and dual GLP-1/GIP agonists. These work via several mechanisms: in the brain, they reduce hunger and increase satiety; in the stomach, they delay gastric emptying, helping to maintain fullness after a meal; and in the pancreas, they improve insulin response and lower blood glucose. Thus, patients naturally eat smaller portions, have less urge to snack, and experience milder post-meal glucose spikes, which further limits “binge” episodes. This distinguishes modern drugs from old “diet pills,” which often merely overstimulated the body, had high side-effect risks, and were used only short-term. Contemporary incretin preparations are designed for chronic use—they maintain effects long-term but require consistent adherence and lifestyle modification.
There is also a group of drugs acting primarily in the gastrointestinal tract—such as orlistat. This medication inhibits digestive enzymes (pancreatic and gastric lipases) so that some dietary fat is not broken down and cannot be absorbed. Non-digested fats are excreted, thereby reducing caloric intake. It does not directly affect hunger centers in the brain but does “cut out” some dietary energy. The downside is frequent gastrointestinal complaints (fatty stools, diarrhea, gas), especially if fat intake is not reduced, which in practice further motivates dietary compliance.
Another group includes medications affecting neurotransmitters in the central nervous system—they can increase satiety, decrease hunger, and reduce the thoughts about food and “hedonic eating” (eating for reward, not true hunger). This was the mode of action for some older sympathomimetic drugs and some modern medications affecting multiple neurotransmitter pathways. Their effectiveness is based on reducing daily calorie intake, but some were withdrawn from the market because of serious side effects (cardiological or psychiatric), underscoring the importance of long-term safety. Current recommendations emphasize drugs with more selective, better-understood mechanisms, combining weight loss with improvements in metabolic parameters (blood pressure, lipids, glucose). There is also pharmacotherapy targeted at improving tissue insulin sensitivity and stabilizing blood glucose (e.g., for type 2 diabetes or prediabetes patients), indirectly supporting weight control; while not formally classified as obesity drugs, in practice they are used for patients with excess weight, because improved glycemic control reduces hunger swings and binges and enhances utilization of body energy. Some patients require a combination of mechanisms—e.g., simultaneous action on satiety centers and glucose metabolism—to achieve greater weight loss with lower doses of individual substances. Each mechanism offers different benefits and limitations, so choosing a drug is always individualized, considering comorbidities, currently used medications, potential interactions, and the side-effect profile acceptable to each patient.
More broadly, obesity pharmacotherapy can be divided into several functional categories: “satiety” drugs (reducing appetite and increasing fullness), “blocking” drugs (limiting fat absorption or modifying nutrient metabolism), and “regulating” drugs (influencing hormonal and metabolic balance to support lower body weight). The first group mainly includes GLP-1 receptor agonists and newer derivatives, as well as some drugs acting on serotonergic or dopaminergic pathways, characterized by increased satiety and less compulsive overeating, strongly supporting low-calorie diet adherence. The second group covers orlistat and some newer substances being studied for their effects on fat/carbohydrate digestion and absorption. Their effectiveness strongly depends on diet—for high-fat or sugar-rich diets, they may “save” more calories but cause more gastrointestinal symptoms. The third category encompasses many drugs not strictly registered as ‘weight loss meds’ but used due to beneficial metabolic effects, such as drugs for diabetes, insulin resistance, or hormonal disorders (e.g., PCOS). Here, therapy increasingly becomes personalized: the physician, analyzing the patient’s main obesity drivers (late-night snacking, binge eating, severe insulin resistance, coexisting depression, metabolic syndrome), can select the drug best suited to the main problem. The approach for a patient with obesity and type 2 diabetes prioritizing glucose and cardiovascular risk reduction will be different from one for a patient with emotional eating and binging episodes.
Obesity medications work most efficiently as part of a comprehensive therapy program, not in isolation: their role is to “unlock” weight loss in a body adapted to years of excess calories, slowed metabolism, and disordered hunger cues. Understanding how each drug affects the nervous system, gut hormones, digestion, and metabolism allows the patient to realistically expect certain outcomes (weight loss speed, possible side effects, need for long-term use) and to cooperate consciously with the doctor in therapy decisions.
The Most Popular Obesity Medications Available in Poland
Several main groups of obesity medications are available in Poland, differing in mechanism of action, effectiveness, and safety profile. In recent years, the most attention has been drawn to GLP‑1 (glucagon-like peptide‑1) receptor agonists – incretin medications originally used for type 2 diabetes, now widely for obesity treatment. These include liraglutide at obesity-specific doses and newer preparations like semaglutide as once-weekly injections, as well as oral formulations studied in clinical trials.
These medications mimic the natural gut hormone GLP‑1, increasing satiety, decreasing appetite, slowing gastric emptying, and improving glucose-insulin metabolism. Clinical studies show, with proper dosing and lifestyle modification, patients on liraglutide can lose on average 8–10% of body weight, and up to 15% or more with semaglutide at obesity doses, though individual responses vary. In Poland, these medications are mainly prescription, often with initial registration for diabetes, while some have separate regulatory approval for obesity with different dosing and qualification criteria. Clinically, they are particularly recommended for patients with obesity and diabetes, prediabetes, or nonalcoholic fatty liver disease, as they support glycemic control, reduce body weight, and may favorably impact cardiovascular risk.
Common side effects include gastrointestinal issues—nausea, vomiting, diarrhea, gas, and a sense of fullness—that typically subside in a few weeks and are prevented by gradual dose titration and slow eating pace. Rarely, pancreatitis or gallbladder problems occur; thus, medical supervision and caution are required for patients with pancreatic diseases or gallstones.
The second main group is orlistat, which acts locally in the digestive tract by inhibiting lipases (fat-digesting enzymes). About 30% of consumed fat remains unabsorbed and is excreted in the stool, reducing total calories. Orlistat is available in both prescription and lower-dose OTC forms, making it one of the best-known “slimming agents” for patients. However, mean weight reduction is more modest versus GLP‑1 agonists, typically about 3–5% compared to diet alone, although consistent adherence to a low-fat diet can deliver better results. Orlistat’s side effects stem from its mechanism—fatty, oily stools, urgent need for bowel movement, bloating, and diarrhea—especially when high-fat meals are eaten. Long-term use may reduce fat-soluble vitamin absorption (A, D, E, K), so supplementation and nutritional monitoring are recommended. In Poland, orlistat is recommended especially for those who cannot or should not use incretin therapy, or who prefer oral, non-neuroactive medications.
Effectiveness of Pharmacological Treatment of Obesity
Assessing pharmacological obesity treatment effectiveness demands a broader view than simply “pounds lost.” Clinical studies define effective treatment as a loss of at least 5% of baseline weight after 3–6 months, and 10% or more at one year, with improved metabolic parameters. While these amounts may seem small to many, they are clinically meaningful: reducing blood pressure, improving lipid profile, reducing insulin resistance, and lowering type 2 diabetes risk. The latest medications, especially GLP‑1 agonists at appropriate doses, have delivered weight reductions comparable to “light” bariatric surgery in controlled studies—15–20% or more over 12–18 months of therapy. However, such results are seen in highly motivated patients under expert care and participating in intensive lifestyle programs. In clinic practice, the success rate is lower, but still much better than what is achievable with diet and exercise alone.
For comparison, a well-executed non-pharmacological program yields 3–7% weight loss, while adding medications increases this typically by another 5–10 percentage points. There are important differences between medication groups: orlistat-based preparations result in about 5–8% reduction after a year, though some patients do not achieve clinically significant loss due to side effects or trouble staying on a low-fat diet. By contrast, incretin medications—especially semaglutide in obesity-specific doses—have shown mean losses over 12–15% in large randomized trials, with a notable subset achieving 20% or more. Importantly, there are so-called non-responders despite correct use; thus, in clinical practice, checkpoints are established—if after three months at the full dose, there is less than 5% reduction, the doctor usually considers switching or discontinuing therapy.
An important measure is the impact on comorbid diseases. For some, obesity pharmacotherapy makes it possible to cut other medication doses (diabetes or antihypertensives), avoids the need for insulin, and substantially improves sleep apnea. Many studies with GLP‑1 agonists confirm cardiovascular risk reductions, independent of weight loss, enhancing the therapeutic value. Psychological benefits are also significant: for those discouraged by years of failed dieting, observable, stable weight loss improves self-esteem, motivation, and readiness for lifelong habit changes.
The effectiveness of obesity pharmacotherapy is inseparable from treatment duration and continuity. As obesity is chronic, short-term cures rarely yield lasting results. Studies show that on stopping most drugs, gradual weight regain follows—within 6–12 months, 30–80% of lost weight can return, especially if new dietary and exercise habits are not established. Therefore, real effectiveness should be assessed not only at one year but in several years’ perspective, with maintenance strategies (continued treatment, dose adjustment, switching preparations, or phased pharmacological support). The best outcomes are seen in patients who view drugs not as a “boost for fast weight loss” but as a tool for building and maintaining lifestyle changes. By reducing appetite and stabilizing metabolism, it is easier to keep a caloric deficit and form new food rituals, which persist after therapy ends. Functional response—improved physical performance, less joint pain, easier mobility, better sleep, less daytime fatigue—is also crucial. For many, 5–7% body weight loss enables easier movement and further weight reduction. Effectiveness is highly individual—genetics, age, obesity duration, history of “miracle diets,” and concurrent steroid or certain antidepressant use (which encourage weight gain) all play a role. Thus, comparing one’s outcomes to friends’ or online stories is misleading—the same preparation might trigger a 20% loss in one person, just 5–6% in another, under similar recommendations.
Finally, treatment effectiveness must always be considered alongside safety. For some, moderate weight loss with good tolerance is more valuable than a larger loss at the cost of frequent side effects or interrupted therapy. Therefore, doctors usually define realistic goals (e.g., 10–15% in 12–18 months), success criteria (minimum percentage lost, specific health improvement), and follow-up schedules measuring not only pounds but waist circumference, blood pressure, lab results, and subjective well-being. This makes obesity pharmacotherapy a planned, measurable process rather than a chaotic series of “slimming drugs” trials.
Obesity Medications and Heart Safety
Cardiovascular safety is one of the key assessment criteria for obesity medications, as most people with excess weight are already at higher risk of heart attack, stroke, or heart failure. Every new preparation must demonstrate not just weight loss effectiveness but at least a neutral or, ideally, beneficial effect on the cardiovascular system. This applies especially to GLP‑1 agonists (e.g., liraglutide, semaglutide), initially developed as diabetes drugs and thus the subject of many large-scale cardiovascular outcome studies.
In people with type 2 diabetes and high cardiovascular risk, liraglutide and semaglutide reduce the risk of “hard endpoints”—cardiovascular death, nonfatal myocardial infarction, and ischemic stroke. Notably, risk reduction is not solely due to weight loss—these drugs also improve glycemic control, lower blood pressure by a few mmHg, reduce liver steatosis, and somewhat improve lipid profiles.
For treating obesity in people without diabetes, the latest data on semaglutide at obesity doses are promising—the SELECT trial found a significant reduction in risk of further cardiovascular events in those with obesity and prior cardiovascular incidents. In practical terms, this means that, when chosen appropriately, certain incretin medications may not only promote weight loss but actually extend life and reduce future heart attack or stroke risk.
However, not all incretin drugs are automatically “cardioprotective”—heart safety must be evaluated for each substance and dose separately. Also, GLP-1/mimetics frequently increase heart rate by several beats per minute; for most, this is not clinically significant, but in those with severe rhythm disturbances or decompensated heart failure, it requires monitoring and ECG, as well as blood pressure checks. Pharmacological obesity treatment also indirectly benefits the heart by improving metabolic parameters: loss of visceral fat reduces systemic inflammation, enhances endothelial function, and helps lower blood pressure, reducing strain on the heart muscle. Even a 5–10% weight loss can significantly lower blood pressure, reduce left ventricular hypertrophy, and improve exercise tolerance. However, weight loss should be gradual; rapid or extreme loss (via strict diet plus aggressive pharmaceutical therapy) can cause electrolyte imbalances and heart rhythm disorders. Doctors, when planning therapy, account for cardiovascular history, concurrent drugs (beta‑blockers, ACE‑inhibitors, anticoagulants), and possible interactions—while most modern obesity medications have low interaction potential, blood pressure, heart rate, ECG, and cardiac markers should be monitored, especially in those with a history of heart attack, heart failure, coronary disease, or cardiomyopathy.
Not all obesity medications have as well-documented a cardiovascular profile as GLP‑1 agonists, so those with substantial safety trials are preferred in clinical practice. For example, orlistat, which acts locally in the gut to block fat absorption, has no direct effect on the circulatory system, does not raise heart rate or stimulate the nervous system, which is a cardiological plus. However, remember that long-term orlistat use can impair absorption of fat-soluble vitamins (A, D, E, K), and in rare cases may affect blood clotting and vessel health—so supplementation and periodic clotting checks are needed, especially for those on oral anticoagulants. Older centrally-acting, stimulating appetite suppressants were withdrawn because they increased heart attack and stroke risk—a reminder that “strong” slimming effects do not guarantee heart safety. Current standards require large, long-term cardiovascular outcome trials (CVOT) before a drug is broadly registered, and the lack of such data limits recommendations to certain subgroups. In the latest generation of therapies, like dual GLP‑1/GIP or triple GLP‑1/GIP/glucagon agonists, CVOT studies are ongoing; so far, they suggest a favorable metabolic profile (major weight loss, improved lipids and blood pressure), but longer observation is needed for full cardiovascular safety assessment.
For cardiac patients, decisions to start obesity medication must involve their lead physician (e.g., diabetologist, primary care doctor) and cardiologist, especially after a heart attack, angioplasty, stent implantation, rhythm disturbances, or heart failure. Dose adjustments to other medications (antihypertensives, antidiabetics) may be needed as weight improves, to avoid hypotension or hypoglycemia. Safe usage is based on careful qualification (including baseline cardiovascular risk), choosing preparations with confirmed neutral or positive cardiac effects, slow dose titration, monitoring blood pressure, heart rate, and symptoms (chest pain, shortness of breath, palpitations), and integrating lifestyle changes—Mediterranean diet, increased activity, cessation of smoking. This approach maximizes the cardiovascular risk reduction potential of obesity medications while minimizing unwanted cardiac events.
Obesity Medications as Support for a Healthy Lifestyle
Obesity medications are not and should never be treated as a substitute for a healthy lifestyle – their role is to make sustainable changes easier and help overcome biological “defenses” against weight loss. Obesity is a chronic disease with impaired regulation of hunger, satiety, metabolism, and hormones, so willpower and a “checklist diet” are often not enough. Pharmacotherapy may reduce pathologically increased appetite, limit compulsive snacking, stabilize glucose and insulin levels, and reduce physical hunger symptoms, making dietary adherence easier in practice. Patients who previously, after a few weeks of dieting, experienced recurring strong hunger and “yo-yo effect” are, with incretin drugs, often able for the first time to maintain a negative energy balance without feeling constantly hungry and irritable. The drugs thus act as “metabolic support”—lowering barriers, but lifestyle change remains the core therapy. Thus, pharmaceuticals should always be combined with an individualized nutrition plan, gradual increases in physical activity, and work on eating behaviors and food relationships.
A clinical dietitian can adjust caloric intake and meal composition to match the new situation (e.g., lower appetite and slower gastric emptying after GLP‑1 therapy), avoiding nutritional deficits and ensuring enough protein, fiber, healthy fats, and micronutrients. A psychodietitian or psychotherapist can support recognition of emotional eating, binge episodes, or ingrained food reward habits. For many, it is the combination of pharmacotherapy and psychoeducation that is a breakthrough – it is easier to work on habits when hunger and obsessive food thoughts are finally under control.
Obesity drugs also facilitate exercise: less weight and reduced breathlessness, joint pain, or heaviness enable more physical activity that was previously felt as too burdensome. In the first months, gentle, suited-to-ability movement is recommended—walking, pool exercises, light resistance workouts—so pharmacological support goes hand-in-hand with building fitness and well-being. Gradual intensity increases, rather than sudden efforts, better protect joints, limit injury risk, and maintain regularity. The doctor also should include education about sleep, stress, and work hygiene—chronic sleep deprivation and high cortisol amplify appetite and hinder weight loss regardless of medication.
A key element of the “medication as support, not replacement” approach is setting clear, measurable behavioral goals, not just weight goals. Together with the medical team, patients should determine which concrete changes should appear: regular meals (e.g., three main and one to two snacks at set times), at least 150 minutes of moderate activity per week, adequate water intake, limiting alcohol and sugary drinks, and practicing mindful eating. Medications create a “window of opportunity” in which the body responds better to energy deficit, and patients have more psychological resources to build new habits—but making use of this period is crucial, as after stopping the drugs, habits will decide long-term results.
Thus, doctors stress that the obesity treatment plan should cover the whole “patient journey”: preparation (diagnosis, education, realistic expectation setting), intensive weight loss phase, and maintenance phase with possible medication modifications and even more emphasis on lifestyle stabilization. Follow-ups should assess not just weight loss rate, but whether healthy behaviors are maintained: keeping a food diary, planning shopping and meals, scheduling activity in the calendar. These parts are as important as the scale, building a “safety net” for the future.
Obesity medications may also be less effective or well-tolerated during periods of strong stress, lack of sleep, or intense emotions; in such times, stepping up lifestyle efforts and psychological support, rather than quitting therapy, is often best. Well-managed pharmacotherapy also teaches flexibility—patients learn to observe their bodies, distinguish true hunger from cravings, and use lower anxiety to introduce gradual but durable changes (switching sugary drinks for water, changing food preparation methods, using smaller plates, etc.). These daily, seemingly small choices, reinforced by medications, are responsible for long-term metabolic health improvements, not the mere fact of taking drugs. Accordingly, current guidelines speak of “comprehensive obesity therapy”—where pharmacology, diet, exercise, psychotherapy, and education form a cohesive, months-long process targeted at total lifestyle improvement, not just short-term weight reduction.
Summary
Pharmacological obesity treatment is an important option for people who do not achieve results through diet and exercise alone. Available medications act on satiety, glucose levels, or fat absorption, and their use should always be supervised by a physician. The latest research shows that modern obesity drugs are not only effective—they may also benefit the heart. Remember, however, that medications are only a support for comprehensive treatment, which should always include healthy lifestyle and proper habits. Always consult a specialist to choose the right treatment path.
